Exchange: NASDAQ·Updated 02:23 PM EDT
OCS logo

OCS Oculis Holding AG

$12.16
$0.14
(1.17%)
Today
Reported EarningsAug 6
Mkt Cap$814.86M
Vol92,312.00

About OCS

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.
46

Neutral Sentiment

How do you feel about OCS?

Advertisement|Remove ads.